In conclusion, these cohort studies suggest that SS-ILD patients with anti-TRIM21 antibodies have more disease activity compared to patients without these autoantibodies, and that anti-TRIM21 is a possible cause of lung involvement leading to ILD. Here, TRIM21 is linked to interstitial lung disease.